Fecal Calprotectin Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025

Description

Persistence Market Research has recently published an in-depth report on the global Fecal Calprotectin Test Market, offering a comprehensive analysis of the market's key dynamics. The report explores current and emerging trends, growth drivers, potential opportunities, and major challenges, providing stakeholders with valuable insights to support strategic decision-making.

Key Insights:

Fecal Calprotectin Test Market Size (2025E): US$ 4,728.3 Mn
Projected Market Value (2032F): US$ 9,623.7 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 8.9%

Fecal Calprotectin Test Market - Report Scope:

The fecal calprotectin test market focuses on diagnostic tools that detect calprotectin levels in stool, serving as a reliable biomarker for inflammation in the gastrointestinal (GI) tract. These non-invasive tests are essential in distinguishing inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, from functional disorders like irritable bowel syndrome (IBS). As awareness around gastrointestinal health grows, so does the demand for early, accurate, and cost-effective diagnostic solutions. The rise in point-of-care testing and advanced immunoassay technologies is further enhancing the accessibility and efficiency of fecal calprotectin diagnostics.

Market Growth Drivers:

The global fecal calprotectin test market is witnessing strong growth driven by the increasing prevalence of chronic gastrointestinal conditions, including IBD and colorectal cancer. The need for early diagnosis and differentiation between inflammatory and non-inflammatory bowel disorders is a major factor supporting market expansion. Advances in diagnostic technologies, such as enzyme-linked immunoassays and rapid point-of-care tests, have significantly improved test sensitivity and turnaround time. Additionally, growing patient awareness, rising healthcare spending, and broader availability of diagnostic services in developing regions are contributing to the market's upward trajectory.

Market Restraints:

Despite promising growth, the market faces several challenges that could hinder its full potential. In many developing regions, limited awareness and insufficient reimbursement frameworks restrict access to advanced diagnostic testing. Variability in test results across different methods and manufacturers can affect clinical trust and widespread adoption. Moreover, the process of collecting and handling stool samples may deter some patients, and logistical difficulties in decentralized healthcare systems can further impede test utilization, especially in rural or under-resourced settings.

Market Opportunities:

The market presents robust opportunities for growth, particularly with the rise of home-based and mobile diagnostic solutions that enable broader access and convenience. Emerging markets in Asia-Pacific and Latin America, where healthcare infrastructure is rapidly evolving, offer significant untapped potential. Continued innovation in biomarker research and diagnostic platforms opens doors for more precise, multi-marker assays tailored to diverse clinical needs. Strategic partnerships with healthcare providers and research institutions, along with investments in product development, can help companies expand their reach and offer more integrated diagnostic solutions to global populations.

Key Questions Answered in the Report:

What are the primary drivers of growth in the global fecal calprotectin test market?
Which regional and segmental markets show the highest demand?
How are diagnostic innovations shaping market trends and opportunities?
Who are the leading players, and what competitive strategies are they pursuing?
What are the key trends and projections for the future of this market?

Competitive Intelligence and Business Strategy:

Top companies in the fecal calprotectin test market, such as Thermo Fisher Scientific Inc., BUHLMANN, Epitope Diagnostics Inc., and DRG International Inc., are actively focusing on technological innovation and expanding their product portfolios. These companies are developing faster, more accurate, and user-friendly tests for both laboratory and point-of-care settings. Strategic collaborations with healthcare institutions, expansion into emerging markets, and robust investments in R&D are central to their growth strategies. Furthermore, efforts to secure regulatory approvals and ensure high product quality continue to drive market competitiveness.

Companies Covered in This Report

Epitope Diagnostics Inc.
Hycult Biotech
Actim
OPERON
Svar Life Science
BUHLMANN
DRG International Inc.
ALPCO
Diazyme Laboratories
Thermo Fisher Scientific Inc.

Market Segmentation

By Technique

Enzyme-linked Immunosorbent Assay
Enzyme Fluoroimmunoassay
Immunochromatography
Point-of-care Tests
Others

By Indication

Inflammatory Bowel Disease (IBD)
Irritable Bowel Syndrome (IBS)
Colorectal Cancer
Infections
Others

By End-user

Hospitals & Clinics
Diagnostic Laboratories
Research Institutes
Gastroenterology Centers

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Product Code: PMRREP35197

1. Executive Summary

1.1. Global Fecal Calprotectin Test Market Snapshot, 2025-2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Regulatory Landscape
3.2. Technique Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis

4. Global Fecal Calprotectin Test Market Outlook:

4.1. Key Highlights
- 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Fecal Calprotectin Test Market Outlook: Technique
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Mn) Analysis, By Technique, 2019-2024
- 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025-2032
  - 4.3.3.1. Enzyme-linked Immunosorbent Assay
  - 4.3.3.2. Enzyme Fluroimmunoassay
  - 4.3.3.3. Immunochromatography
  - 4.3.3.4. Point-of-care tests
  - 4.3.3.5. Others
- 4.3.4. Market Attractiveness Analysis: Technique
4.4. Global Fecal Calprotectin Test Market Outlook: Indication
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2024
- 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  - 4.4.3.1. Inflammatory Bowel Disease (IBD)
  - 4.4.3.2. Irritable Bowel Syndrome (IBS)
  - 4.4.3.3. Colorectal Cancer
  - 4.4.3.4. Infections
  - 4.4.3.5. Others
- 4.4.4. Market Attractiveness Analysis: Indication
4.5. Global Fecal Calprotectin Test Market Outlook: End User
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
- 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  - 4.5.3.1. Hospitals & Clinics
  - 4.5.3.2. Diagnostic Laboratories
  - 4.5.3.3. Research Institutes
  - 4.5.3.4. Gastroenterology Centers
- 4.5.4. Market Attractiveness Analysis: End User

5. Global Fecal Calprotectin Test Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region

6. North America Fecal Calprotectin Test Market Outlook:

6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Technique
- 6.2.3. By Indication
- 6.2.4. By End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025-2032
- 6.4.1. Enzyme-linked Immunosorbent Assay
- 6.4.2. Enzyme Fluroimmunoassay
- 6.4.3. Immunochromatography
- 6.4.4. Point-of-care tests
- 6.4.5. Others
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 6.5.1. Inflammatory Bowel Disease (IBD)
- 6.5.2. Irritable Bowel Syndrome (IBS)
- 6.5.3. Colorectal Cancer
- 6.5.4. Infections
- 6.5.5. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 6.6.1. Hospitals & Clinics
- 6.6.2. Diagnostic Laboratories
- 6.6.3. Research Institutes
- 6.6.4. Gastroenterology Centers
6.7. Market Attractiveness Analysis

7. Europe Fecal Calprotectin Test Market Outlook:

7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Technique
- 7.2.3. By Indication
- 7.2.4. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025-2032
- 7.4.1. Enzyme-linked Immunosorbent Assay
- 7.4.2. Enzyme Fluroimmunoassay
- 7.4.3. Immunochromatography
- 7.4.4. Point-of-care tests
- 7.4.5. Others
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 7.5.1. Inflammatory Bowel Disease (IBD)
- 7.5.2. Irritable Bowel Syndrome (IBS)
- 7.5.3. Colorectal Cancer
- 7.5.4. Infections
- 7.5.5. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 7.6.1. Hospitals & Clinics
- 7.6.2. Diagnostic Laboratories
- 7.6.3. Research Institutes
- 7.6.4. Gastroenterology Centers
7.7. Market Attractiveness Analysis

8. East Asia Fecal Calprotectin Test Market Outlook:

8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Technique
- 8.2.3. By Indication
- 8.2.4. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025-2032
- 8.4.1. Enzyme-linked Immunosorbent Assay
- 8.4.2. Enzyme Fluroimmunoassay
- 8.4.3. Immunochromatography
- 8.4.4. Point-of-care tests
- 8.4.5. Others
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 8.5.1. Inflammatory Bowel Disease (IBD)
- 8.5.2. Irritable Bowel Syndrome (IBS)
- 8.5.3. Colorectal Cancer
- 8.5.4. Infections
- 8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 8.6.1. Hospitals & Clinics
- 8.6.2. Diagnostic Laboratories
- 8.6.3. Research Institutes
- 8.6.4. Gastroenterology Centers
8.7. Market Attractiveness Analysis

9. South Asia & Oceania Fecal Calprotectin Test Market Outlook:

9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Technique
- 9.2.3. By Indication
- 9.2.4. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025-2032
- 9.4.1. Enzyme-linked Immunosorbent Assay
- 9.4.2. Enzyme Fluroimmunoassay
- 9.4.3. Immunochromatography
- 9.4.4. Point-of-care tests
- 9.4.5. Others
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 9.5.1. Inflammatory Bowel Disease (IBD)
- 9.5.2. Irritable Bowel Syndrome (IBS)
- 9.5.3. Colorectal Cancer
- 9.5.4. Infections
- 9.5.5. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 9.6.1. Hospitals & Clinics
- 9.6.2. Diagnostic Laboratories
- 9.6.3. Research Institutes
- 9.6.4. Gastroenterology Centers
9.7. Market Attractiveness Analysis

10. Latin America Fecal Calprotectin Test Market Outlook:

10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Technique
- 10.2.3. By Indication
- 10.2.4. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025-2032
- 10.4.1. Enzyme-linked Immunosorbent Assay
- 10.4.2. Enzyme Fluroimmunoassay
- 10.4.3. Immunochromatography
- 10.4.4. Point-of-care tests
- 10.4.5. Others
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 10.5.1. Inflammatory Bowel Disease (IBD)
- 10.5.2. Irritable Bowel Syndrome (IBS)
- 10.5.3. Colorectal Cancer
- 10.5.4. Infections
- 10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 10.6.1. Hospitals & Clinics
- 10.6.2. Diagnostic Laboratories
- 10.6.3. Research Institutes
- 10.6.4. Gastroenterology Centers
10.7. Market Attractiveness Analysis

11. Middle East & Africa Fecal Calprotectin Test Market Outlook:

11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Technique
- 11.2.3. By Indication
- 11.2.4. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025-2032
- 11.4.1. Enzyme-linked Immunosorbent Assay
- 11.4.2. Enzyme Fluroimmunoassay
- 11.4.3. Immunochromatography
- 11.4.4. Point-of-care tests
- 11.4.5. Others
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 11.5.1. Inflammatory Bowel Disease (IBD)
- 11.5.2. Irritable Bowel Syndrome (IBS)
- 11.5.3. Colorectal Cancer
- 11.5.4. Infections
- 11.5.5. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 11.6.1. Hospitals & Clinics
- 11.6.2. Diagnostic Laboratories
- 11.6.3. Research Institutes
- 11.6.4. Gastroenterology Centers
11.7. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Structure
- 12.1.1. Competition Intensity Mapping By Market
- 12.1.2. Competition Dashboard
12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.2.1. Epitope Diagnostics Inc.
  - 12.2.1.1. Overview
  - 12.2.1.2. Segments and Techniques
  - 12.2.1.3. Key Financials
  - 12.2.1.4. Market Developments
  - 12.2.1.5. Market Strategy
- 12.2.2. Hycult Biotech
- 12.2.3. Actim
- 12.2.4. OPERON
- 12.2.5. Svar Life Science
- 12.2.6. BUHLMANN
- 12.2.7. DRG International Inc.
- 12.2.8. ALPCO
- 12.2.9. Diazyme Laboratories
- 12.2.10. Thermo Fisher Scientific Inc.
- 12.2.11. Others

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations

Fecal Calprotectin Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032